Literature DB >> 26239498

MicroRNA-210 is upregulated by hypoxia-inducible factor-1α in the stromal cells of giant cell tumors of bone.

Shibing Guo1, Rui Bai1, Wanlin Liu1, Aiqing Zhao2, Zhenqun Zhao1, Yuxin Wang1, Yong Wang1, Wei Zhao1, Wenxuan Wang1.   

Abstract

To date, little is known regarding the molecular mechanisms underlying the deregulation of the giant cell tumor of bone (GCTB). Hypoxia has been confirmed to be a characteristic observed in a variety of types of cancer, and a pivotal role for hypoxia‑inducible factor-1α (HIF‑1α) has previously been indicated in the hypoxia adaptation of GCTBs. However, another key regulator, microRNA (miR)‑210, which is closely correlated with HIF‑1α, has not previously been identified in GCTBs. The present study therefore selected miR‑210, the most significantly upregulated miRNA in hypoxic subtypes of cancer, for investigation in GCTB tissues. Reverse transcription-quantitative polymerase chain reaction was used to evaluate miR‑210 expression levels in GCTB tissues and primary GCTB stromal cells. It was revealed that miR‑210 and HIF‑1α were upregulated in GCTB specimens and in primary GCTB stromal cells under hypoxia, and a positive correlation was identified between the two molecules. Furthermore, the promotion of miR‑210 expression in primary GCTB stromal cells by hypoxia was HIF‑1α‑dependent. To the best of our knowledge, the present study was the first to identify the overexpression of miR‑210 in an HIF‑1α‑dependent manner in GCTB specimens, suggesting an adaptive response to hypoxia in GCTB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26239498     DOI: 10.3892/mmr.2015.4170

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

1.  Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease.

Authors:  Virginia Albiñana; Rosa María Jiménez Escribano; Isabel Soler; Luis Rodríguez Padial; Lucia Recio-Poveda; Karina Villar Gómez de Las Heras; Luisa María Botella
Journal:  Orphanet J Rare Dis       Date:  2017-06-29       Impact factor: 4.123

2.  HIF‑1α‑induced upregulation of lncRNA UCA1 promotes cell growth in osteosarcoma by inactivating the PTEN/AKT signaling pathway.

Authors:  Tengfei Li; Yang Xiao; Tunsheng Huang
Journal:  Oncol Rep       Date:  2018-01-03       Impact factor: 3.906

3.  Identification and functional characterization of circRNA-0008717 as an oncogene in osteosarcoma through sponging miR-203.

Authors:  Xiang Zhou; Dimple Natino; Zili Qin; Dong Wang; Zhen Tian; Xuan Cai; Bo Wang; Xijing He
Journal:  Oncotarget       Date:  2017-12-20

4.  Effects of hypoxic-ischemic pre-treatment on microvesicles derived from endothelial progenitor cells.

Authors:  Wen Zeng; Qiaoling Lei; Jiao Ma; Rong Ju
Journal:  Exp Ther Med       Date:  2020-01-23       Impact factor: 2.447

Review 5.  Small non-coding RNAs-based bone regulation and targeting therapeutic strategies.

Authors:  Ying Yang; Sijie Fang
Journal:  Mol Cell Endocrinol       Date:  2016-11-23       Impact factor: 4.102

6.  Hypoxia-Associated Prognostic Markers and Competing Endogenous RNA Co-Expression Networks in Breast Cancer.

Authors:  Peng-Ju Gong; You-Cheng Shao; Si-Rui Huang; Yi-Fan Zeng; Xiao-Ning Yuan; Jing-Jing Xu; Wei-Nan Yin; Lei Wei; Jing-Wei Zhang
Journal:  Front Oncol       Date:  2020-12-02       Impact factor: 6.244

Review 7.  The Regulatory Roles of MicroRNAs in Bone Remodeling and Perspectives as Biomarkers in Osteoporosis.

Authors:  Mengge Sun; Xiaoya Zhou; Lili Chen; Shishu Huang; Victor Leung; Nan Wu; Haobo Pan; Wanxin Zhen; William Lu; Songlin Peng
Journal:  Biomed Res Int       Date:  2016-03-17       Impact factor: 3.411

8.  MitoKATP regulating HIF/miR210/ISCU signaling axis and formation of a positive feedback loop in chronic hypoxia-induced PAH rat model.

Authors:  Yang Lu; Jing Huang; Shuang Geng; Hao Chen; Cheng Song; Shan Zhu; Su Zhao; Mingli Yuan; Xueying Li; Hongling Hu
Journal:  Exp Ther Med       Date:  2017-02-23       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.